Abstracts the STOP-NIDDM trial was developed to replicate the management of IGT patients over the 3.3-year trial period. The costeffectiveness measures were cost per patient free of diabetes and cost per month free of diabetes. Analyses were performed for the total trial population and three subgroups: high risk for diabetes, high risk for CV disease and high risk for combined diabetes-CV disease. Total direct costs were calculated using standard sources and published literature. Costs and outcomes were discounted at 3% and extensive sensitivity analyses were conducted. RESULTS: The incremental cost per patient free of diabetes (month free of diabetes) was 3032€ (136€) and 829€ (35€) for the total study population and high risk diabetes subgroup respectively. Acarbose treatment dominated (i.e. was more effective, less costly) placebo in subgroups at high CV risk and high combined diabetes-CV risk. Deterministic sensitivity analyses showed that the discount rate for costs and the probability of transition to diabetes had the largest impact on results. CONCLUSIONS: Acarbose treatment significantly reduces the incidence of diabetes and CV events in IGT patients. This clinical advantage is expected to lead to reductions in healthcare costs that exceed the acquisition cost of acarbose, thus resulting in overall cost savings in high risk subgroups for CV disease and combined diabetes-CV disease. For the total study population and the high risk diabetes subgroup, savings from fewer cases of diabetes and CV events partly offset the cost of acarbose.
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PDB34 A PHARMACOECONOMIC ANALYSIS OF THE USE OF AN INTENSIVE STRATEGY FOR TREATMENT OF PATIENTS WITH DIABETES MELLITUS TYPE 2 (DM T2)
Smirnova OM 1 , Komarova VP 2 1 Endocrinology Research Center, Moscow, Russia; 2 Aventis Pharma, Moscow, Russia OBJECTIVE: To estimate the cost of intensive treatment of DM T2patients (insulin therapy and combined treatment with insulin and oral hypoglycemic agents (OHAs)). METHODS: The study was conducted for 24 weeks and included 4 visits. In total, 153 patients in DM T2 were examined (65% women and 35% men). The average age was 56.7 years, the duration of the disease was 9.5 years. The cost of treatment included: the cost of patient observation, daily test monitoring, diagnostic manipulations and consultations and cost of the medicines used. Analysis of expenditures was conducted using the incremental cost estimation method that takes into account only the changing quantities. RESULTS: All the patients were divided into two groups in dependence on the result obtained: group 1 (85 pts.), with a level of HbA1c < or = 7.0%, and group 2 (68 pts.), with a level of HbA1c > 7% (p = 0.2784). In group 1, 60 patients received insulin monotherapy and 25-a combination of insulins and OHAs. In group 2, these subgroups counted 34 and 34 patients, respectively. The intensive treatment was associated with increases in the patient management costs by USD 0.89/patient in group 1 and USD 0.78/patient group 2. The cost of treatment increased because of an increase in the consumption of insulin and expenditures on intensive observation. CONCLUSION: The cost of achieving the clinical efficacy criteria in the group where optimal glycemic control was achieved turned out to be comparable with the cost of managing patients in the group where this control was not achieved. However, in group 1, a decrease in the cost of treatment of concurrent diseases was noted. Thus, proof was obtained: glycemic control is the major determinant of the development of cardiovascular complications of advanced DM.
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PDB24 CONTINGENT VALUATION OF AN INHALED DELIVERY SYSTEM FOR INSULIN
Sadri H, MacKeigan L, Einarson TR, Leiter LA University of Toronto, Toronto, ON, Canada OBJECTIVES: Various delivery systems for inhaled insulin (INI) are under development. However, they will likely be substantially more expensive than subcutaneous insulin (SCI). Whether this increased cost is justified is an important question which can be addressed through Contingent Valuation (CV), a survey technique that elicits individuals' preferences for non-marketed products in terms of the amount they would be willing-to-pay. The purpose of this study was to assess diabetic (DM) patients' preference and willingness-to-pay (WTP) for INI. METHODS: A face-to-face CV survey was administered to 96 type-1 and type-2 adult DM patients at St. Michael's Hospital (Toronto, Canada) who were taking insulin and/or oral antihyperglycaemic drugs. Standardized information about INI and SCI was provided by video, and participant's WTP was elicited using "payment scale" method, along with socioeconomic and clinical data. Published data was used to define INI attributes. The CV questionnaire received expert review for content validity and was pilot tested with 22 patients. RESULTS: Participants were 51.8 ± 13.4 years old, and had DM for an average of 11.8 ± 7.8 years; 77 had type-2 and 19 had type-1 DM. Significantly more participants (89%) preferred INI over SCI (P < 0.01). The mean monthly WTP for INI ($153.70 ± $99.90) was significantly more than typical SCI cost of $50 (P < 0.01). A greater proportion of type-2 patients (n = 72/77) preferred INI than did type-1 patients (P < 0.001). The mean WTP for INI in type-2 subgroup ($177.10 ± $91.60) was significantly more compared to type-1 ($154 ± $66.6, P = 0.025). Significantly more participants who were not on insulin preferred INI compared to participants using insulin (P < 0.001). Multiple-regression analysis showed strong association between participants' income and insulin experience and their WTP for INI (P < 0.001). CONCLUSIONS: DM patients prefer INI over SCI and are willing-to-pay significantly more per month than the cost of SCI. Preferences are stronger in type-1 patients DM and those with prior insulin experience.
PDB25
QUALITY OF LIFE IN SUBJECTS WITH AND WITHOUT TYPE-2 DIABETES MELLITUS
Perelli Cippo P, Scalone L, Micheletti S, Mantovani LG University of Milan, Milan, Italy OBJECTIVES: Type-2 diabetes mellitus is a chronic and progressive disease with a negative impact on quality of life. Objectives of the present study were to describe Health-Related Quality of life (HRQOL) in type-2 diabetes mellitus and to compare the health state between diabetic and non-diabetic subjects. METHODS: Type-2 diabetes mellitus patients were selected from a representative sample of the Italian general population aged from 40 to 79 years enrolled in a population based naturalistic prospective survey. We matched each of them by age and sex with a non-diabetic subjects. The EuroQoL (EQ-5D), a self-administered generic questionnaire, completed during the enrolment visit, was used to evaluate HRQOL. RESULTS: We analyzed two groups of 157 subjects each (diabetic and nondiabetic group). The mean age was 63.0 years, 94 (59.9) were male. Diabetic patients reported more problems than nondiabetic subjects in the physical sphere, specifically for mobility and usual activities (P = 0.027 and P = 0.006 respectively), while in self care, pain/discomfort and anxiety/depression dimensions, there was no statistically significant difference between the two groups. Mean values of the visual analogue scale assessing global health status indicated by patients with and without type-2 diabetes mellitus were 70 (SD, ±16.92) and 72 (SD, ±16.75), respectively (P = 0.395). CONCLUSIONS: This study, comparing diabetic and non-diabetic patients of the same age and sex, suggest that the presence of type-2 diabetes mellitus is associated with higher problems in the physical sphere, specifically in domains such as mobility and usual activities, but not on the overall perception of health status.
PDB26 THE IMPACT OF VASCULAR EVENTS ON HEALTH-RELATED UTILITY IN PATIENTS WITH AND WITHOUT TYPE-2 DIABETES
Currie CJ 1 , Peters JR 1 , Morrissey M 1 , Bergenheim K 2 , McEwan P 3 1 Cardiff Research Consortium, Cardiff, Wales, UK; 2 AstraZeneca, Molndal, Sweden; 3 University Hospital of Wales, Cardiff, Wales, UK OBJECTIVES: Health-related utility is a numerical measure of individual satisfaction with health status or health care, and is routinely used for economic evaluation of new drugs. This study measured health-related utility in patients with type-2 diabetes and co-morbidities, such as multiple vascular events, and compared it with utility in non-diabetic patients with similar events. METHODS: Data were taken from the Health Outcomes Data Repository, which includes medical histories, biochemistry, health-related utility (based on the EuroQol-5D), and demographic data for a large population in the UK. The data used here (n = 14,775; 8.3% with type-2 diabetes) were from hospital inpatients and outpatients. RESULTS: The mean healthrelated utility score was lower in diabetic patients compared with non-diabetic patients (0.53 vs. 0.67). The mean utility score for acute myocardial infarction was 0.58 for those with diabetes compared with 0.56 for non-diabetic patients. Respective scores were 0.44 and 0.50 for heart failure; 0.46 and 0.53 for angina; 0.46 and 0.52 for stroke; 0.52 and 0.56 for transient ischaemic attacks; and 0.44 versus 0.51 for renal failure. The mean utility scores for peripheral vascular disease were similar in both groups (0.44 with diabetes and 0.43 without diabetes). The greatest difference was in eyesight diagnoses, with utility scores of 0.50 for diabetic versus 0.64 for non-diabetic patients. The mean utility score was lower (0.58 ± 0.34) for patients with diabetes and no vascular events compared with patients with neither diabetes nor a vascular event (0.70 ± 0.31). Utility scores decreased with increasing number of complications. The difference between diabetes and non-diabetes scores decreased with increasing disease severity, from 0.07 with one event to -0.01 with ≥3 events. CONCLUSIONS: Type-2 diabetes is associated with decreased utility, which is affected by the degree of co-morbidity. These findings could affect how multiple vascular complications states should be valued in economic models.
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DIABETES-Health Policy PDB27 A MULTIDIMENSIONAL HEALTH CARE INTERVENTION ASSESSMENT: THE CO-ORDINATED DIABETES HEALTHCARE NETWORK
Da Costa E 1 , Jasso Mosqueda G 2 , Lemasson H 2 , Roche B 1 , Guerraoui A 1 , Aguilera D 1 , Chicoye A 3 1 Centre hospitalier de Vichy, Vichy, Auvergne, France; 2 AREMIS Consultants, Member of Aegisnet, Neuilly Sur Seine, Ile de France, France; 3 Aremis Consultants, Member of Aegisnet Disease management assessment involves several steps: diagnosis, short and long term studies. From the hospital educational experience conducted in Vichy, hospital and office based practitioners developed a coordinated and multidisciplinary therapeutic educational approach, the "Vichy Diabète healthcare network". Two assessment steps have been conducted. OBJEC-TIVES: Initial objective was to analyse the "hospital therapeutic education program" on diabetic patients knowledge and to identify ways for improvement. The objective of the second step was to validate, after a few months, the choices made by the network. METHODS: Qualitative and quantitative studies were based on data currently collected, questionnaires submitted to diabetic patients who followed the hospital program and practitioners who belong to the network. RESULTS: Initial assessment showed that the hospital program impact alone is modest. A total of 67% of the patients considered that diabetes is a severe disease; 68% estimated that they do their best to treat themselves; 60% declared that the treatment is difficult in every day life, 50% hadn't changed their behaviour since the diabetes diagnostic; 21% didn't know the potential complications. This underlined the need to develop the "Vichy Diabète network". The second step confirmed these observations; 87.9% of interviewed practitioners estimated that patients could improve their behaviour. According to them, respectively 57.5% and 66.7% didn't know well the targeted glycaemia and HbA1C definition, 42.4% thought that diabetes isn't a severe disease. Adherence to diet and physical activity recommendations is considered very insufficient. Thus, according to patients and practitioners, the "Vichy Diabète network" answered to their needs and expectations. CONCLUSIONS: Assessment approach conducted at different steps is particularly adapted to networks project. It brings a lot of information to network care givers on strategic choices and impact on health organisation.
PDB28
VALIDATION OF ORAL ANTIDIABETIC DRUGS PRESCRIPTIONS: THE VIEWS OF PRIMARY CARE PHYSICIANS
Gutierrez L 1 , Magaz S 1 , Badia X 2 1 Health Outcomes Policy and Economics, Barcelona, Spain; 2 Health Outcomes Research Europe Group, Barcelona, Spain OBJECTIVES: To assess views of primary care physicians (PCP's) in Spain regarding the purposes and impact of inspection validation of prescriptions (IVP) (in Spain known as "inspector visa") prior to dispensing within the NHS, in general and particularly in type-2 diabetes mellitus (T2DM) drugs, and to what extent they are in favour of this control mechanism. METHODS: A telephone survey was conducted during October-November, 2003 of 1471 PCP's prescribing an oral antidiabetic requiring IVP, or being familiar with it. Sample sizes per stratum (Autonomous Region) were calculated with a precision of 10% and an alpha-error of 0.05. Data was weighted in order to keep representativeness at a regional and a national level. RESULTS: A total of 40.6% of the 3618 PCP's contacted agreed to participate in the study and met inclusion criteria. On average, they prescribe 30.6 drugs requiring IVP per month, and costs of time invested in tasks related to IVP are estimated around 33€ million annually in primary care. Twenty percent (20%) of PCP's declared that IVP put patients at risk of not receiving the appropriate treatment when they need it, and 56.5% believe that IVP could delay the onset of treatment with T2DM drug. Regarding T2DM drugs, 18.8% of PCP's believed that Health Authorities imposed the IVP requirement to ensure its appropriate utilisa-
